RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
164 hedge funds and large institutions have $1.46B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 39 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
164
Holders Change
+6
Holders Change %
+3.8%
% of All Funds
3.6%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
26
Increased
65
Reduced
39
Closed
20
Calls
$21.3M
Puts
$54.7M
Net Calls
-$33.3M
Net Calls Change
-$14.2M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.2M |
| 2 |
DFO
Duquesne Family Office
New York
|
+$13.9M |
| 3 |
AA
Alta Advisers
London,
United Kingdom
|
+$12.9M |
| 4 |
SPC
Slate Path Capital
New York
|
+$9.64M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.55M |
